7:20 AM
 | 
Oct 12, 2017
 |  BC Extra  |  Financial News

Rare endocrine play Spruce emerges from stealth

Spruce Biosciences Inc. (San Francisco, Calif.) revealed a $20 million series A round of funding and said it has begun enrolling patients in a U.S. Phase...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >